Adios To Alcon In April As Novartis Confirms Spin-Off Date
With the eye-care business set for its own stock exchange listings next month and the future of Sandoz the subject of much discussion, Novartis' plan to be a pure play pharma firm moves ever closer.
You may also be interested in...
Following first anniversary of Lumify launch, "we're still in a pretty heavy investment period supporting trial because our data suggest that when people use the product, they persist in using the product. And so for now, we got our foot down on of the promotional side," says CFO Paul Herendeen.
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
The Swiss major has got off to a strong start in 2019 with Cosentyx and Entresto sales soaring and Mayzent – and possibly very soon Zolgensma – getting US approvals.